
Releases
Pomerantz LLP Launches Investigation Into Ionis Pharmaceuticals
Ionis Pharmaceuticals shares plummeted 23.9% on July 9, 2026, after the company revealed its late-stage CARDIO-TTransform trial for the amyloid cardiomyopathy treatment Wainua failed to hit its primary endpoint. The stock dropped $20.19 to close at $64.27, triggering a formal inquiry by the law firm Pomerantz LLP.





















